APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Softgel CDMO

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Softgel CDMO Market Outlook and Growth Opportunities 2026

Report ID 174479370412 August 2026195 pages

Choose your research edition.

Industry ResearchSoftgel CDMO Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Softgel CDMO Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Softgel CDMO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Softgel CDMO Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Softgel CDMO Market Analysis and Forecast 2026-2032173 pages · $4,950 USD

Market perspective

The global Softgel CDMO market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Softgel CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Softgel CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Softgel CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Softgel CDMO market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Softgel CDMO market include Procaps, Patheon, NextPharma, Lonza, Samsung Biologics, Fareva, WuXi AppTech, WuXi Biologics and Siegfried, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Softgel CDMO market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Softgel CDMO and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Softgel CDMO revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Softgel CDMO market.

Softgel CDMO Segment by Company

Procaps

Patheon

NextPharma

Lonza

Samsung Biologics

Fareva

WuXi AppTech

WuXi Biologics

Siegfried

Catalent

Aenova

Sirio Pharma

Softgel CDMO Segment by Type

Pharmaceutical Softgel CDMO

Nutraceutical Softgel CDMO

Others

Softgel CDMO Segment by Application

Pharmaceutical Company

Biotechnology Company

Others

Softgel CDMO Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Softgel CDMO status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Softgel CDMO key companies, revenue, market share, and recent developments.

3. To split the Softgel CDMO breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Softgel CDMO market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Softgel CDMO significant trends, drivers, influence factors in global and regions.

6. To analyze Softgel CDMO competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Softgel CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Softgel CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Softgel CDMO.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Softgel CDMO industry.

Chapter 3: Detailed analysis of Softgel CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Softgel CDMO in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Softgel CDMO in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Softgel CDMO Industry Trends Table 2. Softgel CDMO Industry Drivers Table 3. Softgel CDMO Industry Opportunities and Challenges Table 4. Softgel CDMO Industry Restraints Table 5. Global Softgel CDMO Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Softgel CDMO Revenue Share by Company (2021-2026) Table 7. Global Softgel CDMO Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Softgel CDMO Key Company Manufacturing Base & Headquarters Table 9. Global Softgel CDMO Company, Product Type & Application Table 10. Global Softgel CDMO Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Softgel CDMO by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Pharmaceutical Softgel CDMO Table 15. Significant Companies of Nutraceutical Softgel CDMO Table 16. Significant Companies of Others Table 17. Global Softgel CDMO Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Softgel CDMO Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Softgel CDMO Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Softgel CDMO Sales Value Share by Type (2021-2026) Table 21. Global Softgel CDMO Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Pharmaceutical Company Table 23. Significant Companies of Biotechnology Company Table 24. Significant Companies of Others Table 25. Global Softgel CDMO Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Softgel CDMO Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Softgel CDMO Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Softgel CDMO Sales Value Share by Application (2021-2026) Table 29. Global Softgel CDMO Sales Value Share by Application (2027-2032) Table 30. Global Softgel CDMO Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Softgel CDMO Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Softgel CDMO Sales Value Share by Region (2021-2026) Table 33. Global Softgel CDMO Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Softgel CDMO Sales Value Share by Region (2027-2032) Table 35. Global Softgel CDMO Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Softgel CDMO Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Softgel CDMO Sales Value Market Share by Country (2021-2026) Table 38. Global Softgel CDMO Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Softgel CDMO Sales Value Market Share by Country (2027-2032) Table 40. Procaps Company Information Table 41. Procaps Business Overview Table 42. Procaps Softgel CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Procaps Softgel CDMO Product Portfolio Table 44. Procaps Recent Development Table 45. Patheon Company Information Table 46. Patheon Business Overview Table 47. Patheon Softgel CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Patheon Softgel CDMO Product Portfolio Table 49. Patheon Recent Development Table 50. NextPharma Company Information Table 51. NextPharma Business Overview Table 52. NextPharma Softgel CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. NextPharma Softgel CDMO Product Portfolio Table 54. NextPharma Recent Development Table 55. Lonza Company Information Table 56. Lonza Business Overview Table 57. Lonza Softgel CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Lonza Softgel CDMO Product Portfolio Table 59. Lonza Recent Development Table 60. Samsung Biologics Company Information Table 61. Samsung Biologics Business Overview Table 62. Samsung Biologics Softgel CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Samsung Biologics Softgel CDMO Product Portfolio Table 64. Samsung Biologics Recent Development Table 65. Fareva Company Information Table 66. Fareva Business Overview Table 67. Fareva Softgel CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Fareva Softgel CDMO Product Portfolio Table 69. Fareva Recent Development Table 70. WuXi AppTech Company Information Table 71. WuXi AppTech Business Overview Table 72. WuXi AppTech Softgel CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. WuXi AppTech Softgel CDMO Product Portfolio Table 74. WuXi AppTech Recent Development Table 75. WuXi Biologics Company Information Table 76. WuXi Biologics Business Overview Table 77. WuXi Biologics Softgel CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. WuXi Biologics Softgel CDMO Product Portfolio Table 79. WuXi Biologics Recent Development Table 80. Siegfried Company Information Table 81. Siegfried Business Overview Table 82. Siegfried Softgel CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Siegfried Softgel CDMO Product Portfolio Table 84. Siegfried Recent Development Table 85. Catalent Company Information Table 86. Catalent Business Overview Table 87. Catalent Softgel CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Catalent Softgel CDMO Product Portfolio Table 89. Catalent Recent Development Table 90. Aenova Company Information Table 91. Aenova Business Overview Table 92. Aenova Softgel CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 93. Aenova Softgel CDMO Product Portfolio Table 94. Aenova Recent Development Table 95. Sirio Pharma Company Information Table 96. Sirio Pharma Business Overview Table 97. Sirio Pharma Softgel CDMO Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 98. Sirio Pharma Softgel CDMO Product Portfolio Table 99. Sirio Pharma Recent Development Table 100. Research Programs/Design for This Report Table 101. Authors List of This Report Table 102. Secondary Sources Table 103. Primary Sources List of Figures Figure 1. Softgel CDMO Product Image Figure 2. Global Softgel CDMO Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Softgel CDMO Market Size (2021-2032) & (US$ Million) Figure 4. Global Softgel CDMO Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Pharmaceutical Softgel CDMO Image Figure 8. Nutraceutical Softgel CDMO Image Figure 9. Others Image Figure 10. Global Softgel CDMO Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Softgel CDMO Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Softgel CDMO Sales Value Share by Type (2021-2032) Figure 13. Pharmaceutical Company Image Figure 14. Biotechnology Company Image Figure 15. Others Image Figure 16. Global Softgel CDMO Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Softgel CDMO Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Softgel CDMO Sales Value Share by Application (2021-2032) Figure 19. Global Softgel CDMO Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Softgel CDMO Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Softgel CDMO Sales Value (2021-2032) & (US$ Million) Figure 22. North America Softgel CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Softgel CDMO Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Softgel CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Softgel CDMO Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Softgel CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Softgel CDMO Sales Value (2021-2032) & (US$ Million) Figure 28. South America Softgel CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Softgel CDMO Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Softgel CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Softgel CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Softgel CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Softgel CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Softgel CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Softgel CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Softgel CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Softgel CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Softgel CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Softgel CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Softgel CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Softgel CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Softgel CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Softgel CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Softgel CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Softgel CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Softgel CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Softgel CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Softgel CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Softgel CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Softgel CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Softgel CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Softgel CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Softgel CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Softgel CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Softgel CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Softgel CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Softgel CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Softgel CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Softgel CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Softgel CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Softgel CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Softgel CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Softgel CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Softgel CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Softgel CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Softgel CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Softgel CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Softgel CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Softgel CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Softgel CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Softgel CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Softgel CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Softgel CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Softgel CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Softgel CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Softgel CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Softgel CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Softgel CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Softgel CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Softgel CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Softgel CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Softgel CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Softgel CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Softgel CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Softgel CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Softgel CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Softgel CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Softgel CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Softgel CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Softgel CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Softgel CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Softgel CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Softgel CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Softgel CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Softgel CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Softgel CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Softgel CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Softgel CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Softgel CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Softgel CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Softgel CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Softgel CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Softgel CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Softgel CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Softgel CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Softgel CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Softgel CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Softgel CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Softgel CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Softgel CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Softgel CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Softgel CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Softgel CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Softgel CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Pharmaceutical Softgel CDMO
  • Nutraceutical Softgel CDMO
  • Others
Applications
  • Pharmaceutical Company
  • Biotechnology Company
  • Others
Companies covered
  • Procaps
  • Patheon
  • NextPharma
  • Lonza
  • Samsung Biologics
  • Fareva
  • WuXi AppTech
  • WuXi Biologics
  • Siegfried
  • Catalent
  • Aenova
  • Sirio Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Softgel CDMO Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Softgel CDMO Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Softgel CDMO Market Dynamics
  1. 2.1 Softgel CDMO Industry Trends
  2. 2.2 Softgel CDMO Industry Drivers
  3. 2.3 Softgel CDMO Industry Opportunities and Challenges
  4. 2.4 Softgel CDMO Industry Restraints
3 Softgel CDMO Market by Company
  1. 3.1 Global Softgel CDMO Company Revenue Ranking in 2025
  2. 3.2 Global Softgel CDMO Revenue by Company (2021-2026)
  3. 3.3 Global Softgel CDMO Company Ranking (2024-2026)
  4. 3.4 Global Softgel CDMO Company Manufacturing Base and Headquarters
  5. 3.5 Global Softgel CDMO Company Product Type and Application
  6. 3.6 Global Softgel CDMO Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Softgel CDMO Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Softgel CDMO Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Softgel CDMO Market by Type
  1. 4.1 Softgel CDMO Type Introduction
  2. 4.1.1 Pharmaceutical Softgel CDMO
  3. 4.1.2 Nutraceutical Softgel CDMO
  4. 4.1.3 Others
  5. 4.2 Global Softgel CDMO Sales Value by Type
  6. 4.2.1 Global Softgel CDMO Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Softgel CDMO Sales Value by Type (2021-2032)
  8. 4.2.3 Global Softgel CDMO Sales Value Share by Type (2021-2032)
5 Softgel CDMO Market by Application
  1. 5.1 Softgel CDMO Application Introduction
  2. 5.1.1 Pharmaceutical Company
  3. 5.1.2 Biotechnology Company
  4. 5.1.3 Others
  5. 5.2 Global Softgel CDMO Sales Value by Application
  6. 5.2.1 Global Softgel CDMO Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Softgel CDMO Sales Value by Application (2021-2032)
  8. 5.2.3 Global Softgel CDMO Sales Value Share by Application (2021-2032)
6 Softgel CDMO Regional Value Analysis
  1. 6.1 Global Softgel CDMO Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Softgel CDMO Sales Value by Region (2021-2032)
  3. 6.2.1 Global Softgel CDMO Sales Value by Region: 2021-2026
  4. 6.2.2 Global Softgel CDMO Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Softgel CDMO Sales Value (2021-2032)
  7. 6.3.2 North America Softgel CDMO Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Softgel CDMO Sales Value (2021-2032)
  10. 6.4.2 Europe Softgel CDMO Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Softgel CDMO Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Softgel CDMO Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Softgel CDMO Sales Value (2021-2032)
  16. 6.6.2 South America Softgel CDMO Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Softgel CDMO Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Softgel CDMO Sales Value Share by Country, 2025 VS 2032
7 Softgel CDMO Country-level Value Analysis
  1. 7.1 Global Softgel CDMO Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Softgel CDMO Sales Value by Country (2021-2032)
  3. 7.2.1 Global Softgel CDMO Sales Value by Country (2021-2026)
  4. 7.2.2 Global Softgel CDMO Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Softgel CDMO Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Softgel CDMO Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Softgel CDMO Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Softgel CDMO Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Softgel CDMO Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Softgel CDMO Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Softgel CDMO Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Softgel CDMO Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Softgel CDMO Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Softgel CDMO Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Softgel CDMO Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Softgel CDMO Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Softgel CDMO Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Softgel CDMO Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Softgel CDMO Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Softgel CDMO Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Softgel CDMO Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Softgel CDMO Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Softgel CDMO Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Softgel CDMO Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Softgel CDMO Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Softgel CDMO Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Softgel CDMO Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Softgel CDMO Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Softgel CDMO Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Softgel CDMO Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Softgel CDMO Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Softgel CDMO Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Softgel CDMO Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Softgel CDMO Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Softgel CDMO Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Softgel CDMO Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Softgel CDMO Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Softgel CDMO Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Softgel CDMO Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Softgel CDMO Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Softgel CDMO Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Softgel CDMO Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Softgel CDMO Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Softgel CDMO Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Softgel CDMO Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Softgel CDMO Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Softgel CDMO Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Softgel CDMO Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Softgel CDMO Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Softgel CDMO Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Softgel CDMO Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Softgel CDMO Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Softgel CDMO Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Softgel CDMO Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Softgel CDMO Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Softgel CDMO Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Softgel CDMO Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Softgel CDMO Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Softgel CDMO Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Softgel CDMO Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Softgel CDMO Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Softgel CDMO Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Softgel CDMO Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Softgel CDMO Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Softgel CDMO Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Softgel CDMO Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Softgel CDMO Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Softgel CDMO Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Softgel CDMO Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Softgel CDMO Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Softgel CDMO Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Softgel CDMO Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Softgel CDMO Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Softgel CDMO Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Softgel CDMO Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Softgel CDMO Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Softgel CDMO Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Softgel CDMO Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Softgel CDMO Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Softgel CDMO Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Softgel CDMO Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Softgel CDMO Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Softgel CDMO Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Softgel CDMO Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Softgel CDMO Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Softgel CDMO Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Softgel CDMO Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Softgel CDMO Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Procaps
  2. 8.1.1 Procaps Company Information
  3. 8.1.2 Procaps Business Overview
  4. 8.1.3 Procaps Softgel CDMO Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Procaps Softgel CDMO Product Portfolio
  6. 8.1.5 Procaps Recent Developments
  7. 8.2 Patheon
  8. 8.2.1 Patheon Company Information
  9. 8.2.2 Patheon Business Overview
  10. 8.2.3 Patheon Softgel CDMO Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Patheon Softgel CDMO Product Portfolio
  12. 8.2.5 Patheon Recent Developments
  13. 8.3 NextPharma
  14. 8.3.1 NextPharma Company Information
  15. 8.3.2 NextPharma Business Overview
  16. 8.3.3 NextPharma Softgel CDMO Revenue and Gross Margin (2021-2026)
  17. 8.3.4 NextPharma Softgel CDMO Product Portfolio
  18. 8.3.5 NextPharma Recent Developments
  19. 8.4 Lonza
  20. 8.4.1 Lonza Company Information
  21. 8.4.2 Lonza Business Overview
  22. 8.4.3 Lonza Softgel CDMO Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Lonza Softgel CDMO Product Portfolio
  24. 8.4.5 Lonza Recent Developments
  25. 8.5 Samsung Biologics
  26. 8.5.1 Samsung Biologics Company Information
  27. 8.5.2 Samsung Biologics Business Overview
  28. 8.5.3 Samsung Biologics Softgel CDMO Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Samsung Biologics Softgel CDMO Product Portfolio
  30. 8.5.5 Samsung Biologics Recent Developments
  31. 8.6 Fareva
  32. 8.6.1 Fareva Company Information
  33. 8.6.2 Fareva Business Overview
  34. 8.6.3 Fareva Softgel CDMO Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Fareva Softgel CDMO Product Portfolio
  36. 8.6.5 Fareva Recent Developments
  37. 8.7 WuXi AppTech
  38. 8.7.1 WuXi AppTech Company Information
  39. 8.7.2 WuXi AppTech Business Overview
  40. 8.7.3 WuXi AppTech Softgel CDMO Revenue and Gross Margin (2021-2026)
  41. 8.7.4 WuXi AppTech Softgel CDMO Product Portfolio
  42. 8.7.5 WuXi AppTech Recent Developments
  43. 8.8 WuXi Biologics
  44. 8.8.1 WuXi Biologics Company Information
  45. 8.8.2 WuXi Biologics Business Overview
  46. 8.8.3 WuXi Biologics Softgel CDMO Revenue and Gross Margin (2021-2026)
  47. 8.8.4 WuXi Biologics Softgel CDMO Product Portfolio
  48. 8.8.5 WuXi Biologics Recent Developments
  49. 8.9 Siegfried
  50. 8.9.1 Siegfried Company Information
  51. 8.9.2 Siegfried Business Overview
  52. 8.9.3 Siegfried Softgel CDMO Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Siegfried Softgel CDMO Product Portfolio
  54. 8.9.5 Siegfried Recent Developments
  55. 8.10 Catalent
  56. 8.10.1 Catalent Company Information
  57. 8.10.2 Catalent Business Overview
  58. 8.10.3 Catalent Softgel CDMO Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Catalent Softgel CDMO Product Portfolio
  60. 8.10.5 Catalent Recent Developments
  61. 8.11 Aenova
  62. 8.11.1 Aenova Company Information
  63. 8.11.2 Aenova Business Overview
  64. 8.11.3 Aenova Softgel CDMO Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Aenova Softgel CDMO Product Portfolio
  66. 8.11.5 Aenova Recent Developments
  67. 8.12 Sirio Pharma
  68. 8.12.1 Sirio Pharma Company Information
  69. 8.12.2 Sirio Pharma Business Overview
  70. 8.12.3 Sirio Pharma Softgel CDMO Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Sirio Pharma Softgel CDMO Product Portfolio
  72. 8.12.5 Sirio Pharma Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst